The estimated Net Worth of Partners Viii Lp Inter West... is at least $566 Mille dollars as of 1 April 2014. Partners West owns over 75,376 units of Applied Genetic Technologies Corp stock worth over $566,364 and over the last 11 years Partners sold AGTC stock worth over $0.
Sign up
Partners West AGTC stock SEC Form 4 insiders trading
Partners has made over 1 trades of the Applied Genetic Technologies Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Partners bought 75,376 units of AGTC stock worth $904,512 on 1 April 2014.
The largest trade Partners's ever made was buying 75,376 units of Applied Genetic Technologies Corp stock on 1 April 2014 worth over $904,512. On average, Partners trades about 75,376 units every 0 days since 2014. As of 1 April 2014 Partners still owns at least 1,452,216 units of Applied Genetic Technologies Corp stock.
You can see the complete history of Partners West stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Applied Genetic Technologies Corp
Over the last 11 years, insiders at Applied Genetic Technologies Corp have traded over $12,578,298 worth of Applied Genetic Technologies Corp stock and bought 760,946 units worth $8,946,827 . The most active insiders traders include Plc Gsk, Edward Hurwitz e Ventures, Inc. Med Immune. On average, Applied Genetic Technologies Corp executives and independent directors trade stock every 89 days with the average trade being worth of $18,318. The most recent stock trade was executed by Stephen W Potter on 30 June 2022, trading 8,070 units of AGTC stock currently worth $6,214.
What does Applied Genetic Technologies Corp do?
Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.
What does Applied Genetic Technologies Corp's logo look like?
Complete history of Partners West stock trades at Applied Genetic Technologies Corp
Applied Genetic Technologies Corp executives and stock owners
Applied Genetic Technologies Corp executives and other stock owners filed with the SEC include:
-
Susan B. Washer,
Pres, CEO & Director -
Stephen W. Potter,
VP & Chief Bus. Officer -
Dr. Abraham Scaria Ph.D.,
Chief Scientific Officer -
Gerald Anthony Reynolds,
Chief Accounting Officer, Principal Accounting Officer & Treasurer -
Jonathan I. Lieber M.B.A.,
Chief Financial Officer -
Dr. Terence R. Flotte M.D.,
Co-Founder -
Dr. Richard Jude Samulski Ph.D.,
Co-Founder -
Dr. William W. Hauswirth,
Co-Founder & Member of Ophthalmology Scientific Advisory Board -
Dr. Barry J. Byrne M.D., Ph.D.,
Co-Founder -
Dr. Nicholas Muzyczka,
Co-Founder -
Edward Hurwitz,
Director -
Michael H. Goldstein,
Chief Medical Officer -
Jeffrey D. Chulay,
V.P. & Chief Medical Officer -
Bruce Peacock,
Director -
Ivana Magovcevic Liebisch,
Director -
Lawrence E Bullock,
Chief Financial Officer -
Arnold L Oronsky,
Director -
Anne Vanlent,
Director -
Scott Koenig,
Director -
Mark S Shearman,
Chief Scientific Officer -
James Rosen,
Director -
Brian Krex,
General Counsel -
Patrick Johan Hendrik Stich...,
-
William A. Sullivan,
Chief Financial Officer -
Abraham Scaria,
Chief Scientific Officer -
Stephen W Potter,
Chief Business Officer -
William Aliski,
Director -
Theresa Heah,
Chief Medical Officer -
Matthew Feinsod,
Exec. VP, Global Strat. & Dev. -
Jill Carroll,
Director -
Daniel L Menichella,
V.P. & Chief Business Officer -
David R. Knop,
Director, Process Development -
Plc Gsk,
10% owner -
Ventures, Inc. Med Immune,
10% owner -
Partners Viii Lp Inter West...,
-
Samuel Wu,
Director -
Partners Viii, L.P.Champsi ...,
-
Susan B. Washer,
President and CEO -
Jonathan I Lieber,
Chief Financial Officer -
Gerald Anthony Reynolds,
Chief Accounting Officer -
Yehia Hashad,
Director -
Hope D Oyley Gay,
General Counsel -
James A. Jr. Robinson,
Director -
Susan Schneider,
Chief Medical Officer